{"id":95160,"date":"2024-05-07T12:25:20","date_gmt":"2024-05-07T10:25:20","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/"},"modified":"2024-09-03T13:00:58","modified_gmt":"2024-09-03T11:00:58","slug":"barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/","title":{"rendered":"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023,  40% of the total in the BioRegion of Catalonia"},"content":{"rendered":"<p><b><span data-contrast=\"auto\">Companies connected to the Barcelona Science Park received \u20ac85.4 million in 2023, 38.6% of the total funding in the BioRegion of Catalonia, \u20ac220 million, according to the BioRegion of Catalonia Report, published annually by Biocat.<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559685&quot;:1418,&quot;335559737&quot;:1189,&quot;335559739&quot;:160,&quot;335559740&quot;:257,&quot;469777462&quot;:[6803,7655],&quot;469777927&quot;:[0,0],&quot;469777928&quot;:[1,1]}\">\u00a0<\/span><b><span data-contrast=\"auto\">Private funding was the main source of investment (\u20ac67.7 M), and almost quadruples the public funding achieved in regional, national, and European competitive calls (\u20ac17.7 M).<\/span><\/b><b><span data-contrast=\"none\">\u00a0<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559685&quot;:1418,&quot;335559737&quot;:1189,&quot;335559739&quot;:160,&quot;335559740&quot;:257,&quot;469777462&quot;:[6803,7655],&quot;469777927&quot;:[0,0],&quot;469777928&quot;:[1,1]}\">\u00a0<\/span><b><span data-contrast=\"auto\">InBrain Neuroelectronics leads the ranking in attracting private investment (\u20ac20 M), with the largest operation recorded in the BioRegion of Catalonia in 2023. SOM Biotech (\u20ac17 M) and Nuage (\u20ac12 M) ranked third and fourth, respectively.<\/span><\/b><\/p>\n<p>The entrepreneurial community of the Barcelona Science Park, comprising nearly a hundred start-ups and scale-ups that promote innovation in biomedicine and life sciences, continues to grow steadily, attracting investment and strengthening its role as an essential asset for the sector&#8217;s growth.<\/p>\n<p>According to the operations identified in <a href=\"https:\/\/report.biocat.cat\/\">BioRegion of Catalonia 2023 report<\/a>, of the total capital inv<strong>ested in 2023 in the BioRegion (\u20ac220 M),<\/strong> nearly <strong>40% (\u20ac85.4 M) was concentrated in the Barcelona Science Park<\/strong>, which consolidates it as one of the most dynamic and forward-looking R&amp;D and health ecosystems in Europe.<\/p>\n<p>Although this figure was lower than the <a href=\"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-break-record-after-raising-e142m-in-2022\/\" target=\"_blank\" rel=\"noopener\">\u20ac142 million<\/a> obtained by start-ups and scale-ups linked to the Park during the historic 2022 \u2013 an exceptional year because three record-breaking mega-deals coincided in the BioRegion of Catalonia (<a href=\"https:\/\/www.biocat.cat\/en\/record-funding-health-startups-based-catalonia-eu445-m-investment\" target=\"_blank\" rel=\"noopener\">\u20ac445 M<\/a>) \u2013 <strong>the public and private funding received by these companies in 2023 is more than double the amount achieved in 2021 <\/strong>(<a href=\"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/\" target=\"_blank\" rel=\"noopener\">\u20ac39 M<\/a>). This suggests that the Park\u2019s community continues to attract more investment, despite the difficult global geopolitical and economic environment.<\/p>\n<p>Private funding (venture capital, private equity and venture debt) was the main source of investment (<strong>\u20ac67.7 M<\/strong>), and <strong>almost quadruples the public funding <\/strong>achieved in regional, national and European competitive calls (<strong>\u20ac17.7 M<\/strong>).<\/p>\n<p>The participation of <strong>international capital<\/strong> in funding rounds continues its upward trend. <strong>Half of the 2023 deals involved foreign investors.<\/strong> Furthermore, the <strong>\u20ac27.5 million<\/strong> in venture debt financing provided by the <strong>European Investment Bank (EIB)<\/strong> reflects its willingness to invest in new disruptive projects driven by start-ups and scale-ups with distinctive impact potential.<\/p>\n<p>The <strong>biotechnology <\/strong>and <strong>medical technology <\/strong>sub-sectors, with <strong>\u20ac43.7 and<\/strong> <strong>\u20ac24 million <\/strong>respectively<strong>,<\/strong> led the attraction of private investment in health. The most represented therapeutic areas were the nervous system, oncology and immunology. femtech, emerging technologies for women&#8217;s health, and haematology are attracting increasing interest from investors.<\/p>\n<p>Companies from the University of Barcelona Science Park community have obtained practically half of the financing raised by companies from the BioRegion of Catalonia. This fact, according to the director of the Barcelona Science Park, <strong>Maria Terrades<\/strong>, give a measure of \u201cthe Park\u2019s relevance and position us as a key player and one of the epicentres of this powerful ecosystem.\u201d And he adds that, in fact, these results are proof that the investment sector and public institutions trust the Park entities and their future projection: \u201cwe must continue to work with excellence so that these projects come full circle in our facilities.\u201d<\/p>\n<h3><strong>The largest operation recorded in the BioRegion of Catalonia in 2023<\/strong><\/h3>\n<p><strong>Inbrain Neuroelectronics<\/strong> led the most important operation in terms of funding registered in the BioRegion of Catalonia last year. The ICN2 and ICREA spin-off \u2013 which has created the world&#8217;s first graphene neural interface for the treatment of central nervous system (CNS) diseases \u2013 received a loan of <strong><a href=\"https:\/\/www.eib.org\/en\/projects\/pipelines\/all\/20220924\">\u20ac20 million<\/a> <\/strong>from the European Investment Bank (EIB), with which it will accelerate the clinical development of its R&amp;D programmes for Parkinson&#8217;s disease, epilepsy and speech disorders.<\/p>\n<p><strong>SOM Biotech<\/strong>, specialised in the repositioning of drugs for CNS diseases, closed <strong>the third largest transaction <\/strong>(<strong>\u20ac17 million<\/strong>) in the BioRegion of Catalonia with the EIB (<a href=\"https:\/\/www.eib.org\/en\/projects\/loans\/all\/20220519\" target=\"_blank\" rel=\"noopener\">\u20ac7.5 million<\/a>), the US fund Prevail Partners and the current shareholders. The investment will be used to finance several ongoing projects: the phase IIb clinical trial of SOM3355 for Huntington&#8217;s disease, and the initiation of trials with other molecules in diseases such as tardive dyskinesia (SOM3366) and phenylketonuria (SOM1311).<\/p>\n<p><strong>Nuage Therapeutics<\/strong> took <strong>fourth place in the BioRegion of Catalonia<\/strong>, with the <a href=\"https:\/\/www.pcb.ub.edu\/en\/nuage-therapeutics-gains-e12-million-in-seed-funding\/\" target=\"_blank\" rel=\"noopener\">\u20ac12 million<\/a> obtained in a funding round led by Sofinnova Partners and Asabys, in which the CDTI (Innvierte programme) and Banc Sabadell (Bstartup) also participated. With this capital, the IRB Barcelona and ICREA spin-off aims to promote its project against prostate cancer and to validate its platform for the discovery of drugs that modulate intrinsically disordered proteins (IDPs).<\/p>\n<p><span data-contrast=\"none\">Among the group of companies that received between <\/span><b><span data-contrast=\"none\">\u20ac4 and 10 million<\/span><\/b><span data-contrast=\"none\"> in private funding are OneChain Immunotherapeutics (OCI) and DeepUll.<\/span><span data-contrast=\"auto\">\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">OneChain Immunotherapeutics<\/span><\/b> <b><span data-contrast=\"auto\">(OCI)<\/span><\/b><span data-contrast=\"auto\">, <\/span><span data-contrast=\"none\">a clinical-stage biotech company focused on the development of CAR-T candidates for oncology diseases, <\/span><span data-contrast=\"auto\">closed a pre-series A funding round of <\/span><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/onechain-immunotherapeutics-secures-e6-7m-in-pre-series-a-funding-round\/\" target=\"_blank\" rel=\"noopener\">\u20ac6.7<\/a> million<\/strong><span data-contrast=\"auto\">, led by Invivo Capital, with the participation of existing investors \u2013 the Josep Carreras Leukaemia Foundation and the CDTI \u2013 and two new investors, Nara Capital and Clave Capital. The capital<\/span><span data-contrast=\"none\"> will enable it to complete a unique clinical trial using CAR-T technology for patients with a subtype of T-cell leukaemia.\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">DeepUll<\/span><\/b><span data-contrast=\"none\">, specialising in the development of affordable, culture-free diagnostic solutions for the early identification of sepsis and other acute infections, received <\/span><a href=\"https:\/\/www.pcb.ub.edu\/en\/sabadell-asabys-invests-in-deepull-extending-its-series-b-to-e17m\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac4 million<\/span><\/a> <span data-contrast=\"none\">from<\/span><span data-contrast=\"none\"> Asabys, <\/span><span data-contrast=\"none\">through its Sabadell Asabys Health Innovation Investments II (SAHII II) fund, which builds on the <\/span><span data-contrast=\"none\">\u20ac13 million from a series B funding round held in 2022. These additional funds will allow the company to continue the development of its first-in-class sepsis identification technology platform and path to market.\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Among the start-ups and scale-ups that attracted between <\/span><b><span data-contrast=\"none\">\u20ac1 and 3 million<\/span><\/b><span data-contrast=\"none\"> in private equity are: Omniscope, Zymvol, MiMARK Diagnostics and IDP Pharma.<\/span><span data-contrast=\"auto\">\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">Omniscope<\/span><\/b><span data-contrast=\"none\"> received an investment of <\/span><a href=\"https:\/\/www.foundersxventures.com\/portfolio\"><span data-contrast=\"none\"><strong>\u20ac1.8 million<\/strong><\/span><\/a><span data-contrast=\"none\"> from Silicon Valley-based venture capital firm FoundersX Ventures. Deeptech is building the world&#8217;s largest immunological databank, with high resolution achieved through proprietary sequencing of immune cells and artificial intelligence. Its vertically integrated platform drives innovative therapeutic designs and diagnostic development.\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">Zymvol<\/span><\/b><span data-contrast=\"none\"> closed a seed funding round led by the venture capital firm Elaia Partners with <\/span><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/the-biotechnological-company-zymvol-raises-e1-3-m-and-joins-the-barcelona-science-park\/\" target=\"_blank\" rel=\"noopener\">\u20ac1.3 million<\/a><\/strong><span data-contrast=\"none\">. With this capital injection, the company \u2013 which specialises in computational engineering for enzyme discovery and optimisation \u2013 aims to boost its portfolio and catalyse its widespread use in industry to promote a new generation of products that will lead the transition to a more sustainable future.\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">MiMARK Diagnostics <\/span><\/b><span data-contrast=\"auto\">received a total of <\/span><b><span data-contrast=\"auto\">\u20ac1.27 million. <\/span><\/b><span data-contrast=\"auto\">In a deal led by investment funds Clave Capital, Nara Capital and Namarel Ventures, with participation from the WA4Steam network, it received <\/span><a href=\"https:\/\/www.pcb.ub.edu\/en\/mimark-diagnostics-raises-e1-2m-to-accelerate-the-development-of-its-in-vitro-diagnostic-assay-for-endometrial-cancer\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac1 million<\/span><\/a><span data-contrast=\"none\">. <\/span><span data-contrast=\"auto\">The CDTI also added to the capital of this VHIR spin-off in 2023 with a contribution of <\/span><a href=\"https:\/\/www.cdti.es\/en\/node\/18620\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac270,000<\/span><\/a><span data-contrast=\"auto\">. These funds will allow it to accelerate development of WomEC, its in vitro diagnostic test for endometrial cancer.\u202f\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">IDP Pharma<\/span><\/b><span data-contrast=\"none\"> closed a Capital Cell funding round with <\/span><a href=\"https:\/\/capitalcell.com\/en\/campaign\/idp-pharma\/\"><span data-contrast=\"none\"><strong>\u20ac1.13 million<\/strong><\/span><\/a> <span data-contrast=\"none\">to complete the phase I trial of IDP-121, the first drug capable of blocking and degrading a key oncoprotein in various types of haematological tumours, such as multiple myeloma, the second most frequent and incurable blood cancer. IDP-121 is the first drug capable of blocking and degrading the protein responsible for its onset and progression.\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Other PCB companies that secured investments under <\/span><b><span data-contrast=\"none\">\u20ac1 million<\/span><\/b><span data-contrast=\"none\"> include <\/span><b><span data-contrast=\"none\">Pharmacelera<\/span><\/b><span data-contrast=\"none\"> (<\/span><strong><a href=\"https:\/\/capitalcell.es\/campaign\/pharmacelera-2022\/\">\u20ac922,911<\/a><\/strong><span data-contrast=\"none\">), a deeptech company specialising in disruptive computational chemistry solutions for drug discovery; <\/span><b><span data-contrast=\"none\">Kumux <\/span><\/b><span data-contrast=\"none\">(<\/span><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/beable-capital-invests-500000-euros-in-the-deep-tech-company-kumux\/\" target=\"_blank\" rel=\"noopener\">\u20ac500,000<\/a><\/strong><span data-contrast=\"none\">), another deeptech company that has created an intelligent system of circadian lighting in buildings, which imitates sunlight, to improve people&#8217;s health; and <\/span><b><span data-contrast=\"none\">Connecta Therapeutics <\/span><\/b><span data-contrast=\"none\">(<\/span><a href=\"https:\/\/www.linkedin.com\/posts\/biocat-bioregion-of-catalonia_connecta-therapeutics-capta-33-millones-activity-7071764481634103298-wnAf?utm_source=share&amp;utm_medium=member_desktop\"><span data-contrast=\"none\">\u20ac200,000<\/span><\/a><span data-contrast=\"none\">), a spin-off from the Prous Institute for Biomedical Research focused on new treatments for unmet medical needs in CNS, the most advanced being a drug for fragile X syndrome (FXS), in clinical development.<\/span><span data-contrast=\"none\">\u202f\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<h3><b><span data-contrast=\"none\">A leading hub for attracting public investment in health\u202f<\/span><\/b><span data-contrast=\"none\">\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"none\">Several start-ups and scale-ups at the PCB significantly expanded their financial capacity through competitive regional, national and European calls for proposals. The public funding received by the companies of the PCB community in 2023 reached \u20ac17.7 million, mainly from the European Commission, through various instruments of the European Innovation Council (EIC), and from the NextGenerationEU fund, through public aid programmes of the CDTI and the State Research Agency (AEI).<\/span><span data-contrast=\"none\">\u202f\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">At the top of the ranking is the biotech <\/span><b><span data-contrast=\"none\">OneChain<\/span><\/b><span data-contrast=\"none\">, with <\/span><b><span data-contrast=\"none\">\u20ac3.8 million<\/span><\/b><span data-contrast=\"none\"> (<\/span><a href=\"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac2.5 M<\/span><\/a> <span data-contrast=\"none\">from the<\/span> <span data-contrast=\"none\">EIC Transition funding programme), followed by <\/span><b><span data-contrast=\"none\">MiMARK Diagnostics<\/span><\/b><span data-contrast=\"none\">, with <\/span><b><span data-contrast=\"none\">\u20ac3 million <\/span><\/b><span data-contrast=\"none\">(<\/span><a href=\"https:\/\/www.pcb.ub.edu\/en\/mimark-diagnostics-receives-e2-5-m-from-the-european-innovation-council-accelerator\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac2.5 M<\/span><\/a><span data-contrast=\"auto\"> from the EIC Accelerator funding programme and <\/span><a href=\"https:\/\/www.aei.gob.es\/sites\/default\/files\/convocatory_info\/file\/2023-12\/CPP2022_RC_WEB_FIRMADA.pdf\"><span data-contrast=\"none\">\u20ac589,000<\/span><\/a><span data-contrast=\"auto\"> from the AEI grants for public-private collaboration projects); <\/span><b><span data-contrast=\"auto\">Leanbio, <\/span><\/b><span data-contrast=\"auto\">which received a financial injection of <\/span><b><span data-contrast=\"auto\">\u20ac2.1 million<\/span><\/b><span data-contrast=\"auto\"> under the <\/span><a href=\"https:\/\/www.mintur.gob.es\/PortalAyudas\/IDI-Farma\/Concesion\/2023\/Documents\/LISTADOESTIMADOS%20EVALUACI%C3%93N%20PROVISIONAL_2023_def.pdf\"><span data-contrast=\"none\">PERTE programme;<\/span><\/a><span data-contrast=\"none\">\u00a0<\/span><b><span data-contrast=\"none\">GAT Biosciences<\/span><\/b><span data-contrast=\"none\">,<\/span><span data-contrast=\"auto\"> which attracted<\/span> <b><span data-contrast=\"none\"><a href=\"https:\/\/www.cdti.es\/sites\/default\/files\/2023-10\/resolucion_definitiva_firmado_sello_2022.pdf\" target=\"_blank\" rel=\"noopener\">\u20ac1.9 million<\/a> <\/span><\/b><span data-contrast=\"none\">(<\/span><a href=\"https:\/\/www.cdti.es\/sites\/default\/files\/2023-10\/resolucion_definitiva_firmado_sello_2022.pdf\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">SoE-CDTI <\/span><span data-contrast=\"auto\">call<\/span><\/a><span data-contrast=\"none\">), and <\/span><b><span data-contrast=\"none\">Connecta Therapeutics<\/span><\/b><span data-contrast=\"none\">, with <\/span><b><span data-contrast=\"none\">\u20ac2 million<\/span><\/b><span data-contrast=\"none\"> (<\/span><a href=\"https:\/\/www.aei.gob.es\/sites\/default\/files\/convocatory_info\/file\/2023-09\/CPP2022_PRP_WEB_REV_FIRM.pdf\"><span data-contrast=\"none\">\u20ac1.4 M<\/span><\/a><span data-contrast=\"none\"> from the AEI grants for public-private collaboration projects and <\/span><a href=\"https:\/\/connectatherapeutics.com\/news\/connecta-therapeutics-starts-clinical-trials-for-its-fragile-x-syndrome-drug\/\"><span data-contrast=\"none\">\u20ac600,000<\/span><\/a><span data-contrast=\"none\"> from Enisa).\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Companies that won competitive public calls of less than \u20ac1 million include <\/span><b><span data-contrast=\"none\">Aptadel Therapeutics<\/span><\/b><span data-contrast=\"none\"> (\u20ac981,000), <\/span><b><span data-contrast=\"none\">Nuage Therapeutics<\/span><\/b><span data-contrast=\"none\"> (\u20ac861,000), <\/span><b><span data-contrast=\"none\">Pharmacelera <\/span><\/b><span data-contrast=\"none\">(\u20ac600,000), <\/span><b><span data-contrast=\"none\">Vitala Technologies<\/span><\/b><span data-contrast=\"none\"> (\u20ac704,000), <\/span><b><span data-contrast=\"none\">Bioliquid Innovative Genetics<\/span><\/b><span data-contrast=\"none\"> (\u20ac500,000), <\/span><b><span data-contrast=\"none\">Innervia Bioelectronics<\/span><\/b><span data-contrast=\"none\"> (\u20ac416,000), <\/span><b><span data-contrast=\"none\">GAT Therapeutics<\/span><\/b><span data-contrast=\"none\"> (\u20ac327,000), <\/span><b><span data-contrast=\"none\">Accure Therapeutics<\/span><\/b><span data-contrast=\"none\"> (\u20ac325,000), <\/span><b><span data-contrast=\"none\">Real Deal Milk <\/span><\/b><span data-contrast=\"none\">(\u20ac324,000), <\/span><b><span data-contrast=\"none\">SiTec PharmaBio<\/span><\/b> <span data-contrast=\"none\">(\u20ac15,000),<\/span> <b><span data-contrast=\"none\">Gate2Brain<\/span><\/b><span data-contrast=\"none\"> (\u20ac15,000) and <\/span><b><span data-contrast=\"none\">BeCytes Biotechnologies<\/span><\/b><span data-contrast=\"none\"> (\u20ac6,000).\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">\u202f<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Companies connected to the Barcelona Science Park received \u20ac85.4 million in 2023, 38.6% of the total funding in the BioRegion of Catalonia, \u20ac220 million, according to the BioRegion of Catalonia&#8230;<\/p>\n","protected":false},"author":14,"featured_media":95130,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[38],"tags":[],"class_list":["post-95160","post","type-post","status-publish","format-standard","has-post-thumbnail","category-pcb-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Companies connected to the Barcelona Science Park received \u20ac85.4 million in 2023, 38.6% of the total funding in the BioRegion of Catalonia, \u20ac220 million, according to the BioRegion of Catalonia...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-07T10:25:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-03T11:00:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/PCB.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia\",\"datePublished\":\"2024-05-07T10:25:20+00:00\",\"dateModified\":\"2024-09-03T11:00:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/\"},\"wordCount\":1412,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PCB.jpg\",\"articleSection\":[\"PCB\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/\",\"name\":\"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PCB.jpg\",\"datePublished\":\"2024-05-07T10:25:20+00:00\",\"dateModified\":\"2024-09-03T11:00:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PCB.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PCB.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/","og_locale":"en_US","og_type":"article","og_title":"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia - Parc Cient\u00edfic de Barcelona","og_description":"Companies connected to the Barcelona Science Park received \u20ac85.4 million in 2023, 38.6% of the total funding in the BioRegion of Catalonia, \u20ac220 million, according to the BioRegion of Catalonia...","og_url":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2024-05-07T10:25:20+00:00","article_modified_time":"2024-09-03T11:00:58+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/PCB.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia","datePublished":"2024-05-07T10:25:20+00:00","dateModified":"2024-09-03T11:00:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/"},"wordCount":1412,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/PCB.jpg","articleSection":["PCB"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/","url":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/","name":"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/PCB.jpg","datePublished":"2024-05-07T10:25:20+00:00","dateModified":"2024-09-03T11:00:58+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/PCB.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/05\/PCB.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/barcelona-science-park-companies-receive-e85-4-million-in-investment-in-2023-40-of-the-total-in-the-bioregion-of-catalonia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Barcelona Science Park companies receive \u20ac85.4 million in investment in 2023, 40% of the total in the BioRegion of Catalonia"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/95160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=95160"}],"version-history":[{"count":5,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/95160\/revisions"}],"predecessor-version":[{"id":98020,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/95160\/revisions\/98020"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/95130"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=95160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=95160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=95160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}